Home | Publications | Management / Strategy | Outsourcing place holder
place holder place holder

Outsourcing

Clinical Outsourcing Sponsors Forcing Market Change


Publication Date   June 2005
Publisher   IDC
Product Type   Newsletter
Pages   11
ISBN Number   not applicable
Product Code   IDC002
Ask a question about this product?

Price £1,945.00

approximately: $2,900 | €2,317

Summary


This study examines the shift in sponsor sentiment away from engaging contract research organizations (CROs) for end-to-end contract research services toward a best-of-breed, selective sourcing approach. Pharmaceutical and biotechnology companies are increasingly calling on a wider variety of service providers to prepare bids for outsourcing preclinical and clinical research processes. Some, such as Wyeth and Pfizer, recently declared that they seek a new mix of providers because they are not getting what they want out of the megacontract arrangements they currently have with CROs. Although they won't completely divest themselves of CROs, they expect to decrease the amount of contracts awarded to CROs and phase out existing contracts when they expire.

Content


In This Study
Situation Overview
Table: Selective Sourcing Matrix for Clinical Outsourcing
A Tale of Two Models: Pfizer and Wyeth Make Differing Bets to Revamp Their Outsourcing Strategies
Wyeth-Accenture Engagements Mark Industry Turning Point
Wyeth's Next Steps
Pfizer's Shift from a Full-Service to a Functional Service Provider Approach
Strategies Differ, but Sponsor Preferences for Full-Service Versus Niche Capabilities Have Begun to Align
Figure: Most Important Area in Which CROs Need to Improve
Future Outlook
Essential Guidance
For Sponsors
For Contract Research Organizations
Learn More
Related Research
Synopsis